Aldafermin clinical trials
Also written NGM282.
How each study uses aldafermin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
14 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 1
NGM Biopharmaceuticals, Inc (13) · Michael Camilleri, MD (1)
Studies
Open first, then newest update. How each study uses aldafermin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2NGM Biopharmaceuticals, IncNCT02443116Written as NGM282
- Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)CompletedPhase 2NGM Biopharmaceuticals, IncNCT03912532Written as NGM282
- A Study of NGM282 in Patients With Primary Sclerosing CholangitisCompletedPhase 2NGM Biopharmaceuticals, IncNCT02704364Written as NGM282
- A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.WithdrawnPhase 2/3NGM Biopharmaceuticals, IncNCT06654726Written as aldafermin
- Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)CompletedPhase 2NGM Biopharmaceuticals, IncNCT04210245Written as aldafermin
- Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)CompletedPhase 2Michael Camilleri, MDNCT05130047Written as Aldafermin
- Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese SubjectsCompletedPhase 1NGM Biopharmaceuticals, IncNCT04828265Written as Aldafermin
- Study of Aldafermin (NGM282) in Participants With Impaired Hepatic FunctionCompletedPhase 1NGM Biopharmaceuticals, IncNCT04823702Written as Aldafermin
- Study of Aldafermin (NGM282) in Participants With Impaired Renal FunctionCompletedPhase 1NGM Biopharmaceuticals, IncNCT04179630Written as Aldafermin (NGM282)
- Study of NGM282 in Subjects With Functional Constipation and Healthy IndividualsCompletedPhase 1/2NGM Biopharmaceuticals, IncNCT02649062Written as NGM282
- Phase 2 Study of NGM282 in Patients With Primary Biliary CirrhosisCompletedPhase 2NGM Biopharmaceuticals, IncNCT02026401Written as NGM282
- Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary CirrhosisCompletedPhase 2NGM Biopharmaceuticals, IncNCT02135536Written as NGM282
- Phase 2 Study of NGM282 in Patients With Type 2 DiabetesCompletedPhase 2NGM Biopharmaceuticals, IncNCT01943045Written as NGM282
- Phase 1 SAD and MAD Study of NGM282 in Healthy Adult ParticipantsCompletedPhase 1NGM Biopharmaceuticals, IncNCT01776528Written as NGM282
Codes
What other systems call aldafermin · ClinicalTrials.gg INT001421
- MeSH (NLM) C000710649aldaferminConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) IK9NYN31ZMALDAFERMINConfirmed FDA, NLM
- NCI Thesaurus C169769AldaferminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710649 | aldafermin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | IK9NYN31ZM | ALDAFERMIN | Confirmed FDA, NLM |
| NCI Thesaurus | C169769 | Aldafermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.